The OASIS trial evaluates the efficacy of ibrutinib, venetoclax, and obinutuzumab in newly diagnosed mantle cell lymphoma, reporting a 5-year progression-free survival (PFS) rate of 80% and overall survival...
The OASIS trial evaluates the efficacy of ibrutinib, venetoclax, and obinutuzumab in newly diagnosed mantle cell lymphoma, reporting a 5-year progression-free survival (PFS) rate of 80% and overall survival...
Researchers analyzed data from a nationwide cohort to evaluate the effectiveness of covalent Bruton tyrosine kinase inhibitors, used either as monotherapy or in combination with anti-CD20 monoclonal...
Researchers analyzed data from a nationwide cohort to evaluate the effectiveness of covalent Bruton tyrosine kinase inhibitors, used either as monotherapy or in combination with anti-CD20 monoclonal...
Researchers analyzed data from a nationwide cohort to evaluate the effectiveness of covalent Bruton tyrosine kinase inhibitors, used either as monotherapy or in combination with anti-CD20 monoclonal...
Researchers analyzed data from a nationwide cohort to evaluate the effectiveness of covalent Bruton tyrosine kinase inhibitors, used either as monotherapy or in combination with anti-CD20 monoclonal...
Researchers analyzed data from a nationwide cohort to evaluate the effectiveness of covalent Bruton tyrosine kinase inhibitors, used either as monotherapy or in combination with anti-CD20 monoclonal...
Researchers analyzed data from a nationwide cohort to evaluate the effectiveness of covalent Bruton tyrosine kinase inhibitors, used either as monotherapy or in combination with anti-CD20 monoclonal...
A retrospective study highlights the safety and feasibility of outpatient administration of brexucabtagene autoleucel for patients with acute lymphoblastic leukemia and mantle cell lymphoma, showing...
A retrospective study highlights the safety and feasibility of outpatient administration of brexucabtagene autoleucel for patients with acute lymphoblastic leukemia and mantle cell lymphoma, showing...
